American Society for Dermatologic Surgery Annual Meeting to Include Presentation on the Effectiveness of SRT
BOCA RATON, Fla., October 2, 2017 – Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers (NMSC) and other skin conditions, such as keloids with Superficial Radiation Therapy (SRT), announced today that the 2017 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago will include a presentation on the effectiveness of Superficial Radiation Therapy for keloid treatment. On Oct. 5 at 5:30 to 7 p.m., ASDS will include a poster presentation on the low rate of keloid recurrence following SRT treatment.
“Recurrences after keloidectomy are very common, happening at excision sites in about 71 percent of cases. Because of how difficult they are to treat and this high rate of recurrence, keloids significantly impact a patient’s quality of life,” said Joe Sardano, CEO, Sensus Healthcare. “As SRT is highly effective, safe and non-invasive, it is vital that both patients and doctors learn more about this keloid treatment, which has proven to be life-changing for many patients throughout the country and world.”
Sensus Healthcare’s SRT-100TM delivers precise, calibrated, low-dose radiation that effectively destroys basal cell carcinoma and squamous cell carcinoma, as well as the non-malignant tumor cells that cause keloids. SRT treatment is painless and doesn’t involve cutting, bleeding, stitching or anesthesia. The SRT-100 has been cleared by the USDA for the treatment of non-melanoma skin cancers and keloids.
The 2017 ASDS Annual Meeting is taking place at the Hyatt Regency in Chicago on Oct. 5 through 8. For more information on Sensus Healthcare and the Company’s SRT technology, please visit www.sensushealthcare.com.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiotherapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit https://www.sensushealthcare.com.
About American Society for Dermatologic Surgery
American Society for Dermatologic Surgery (ASDS) is the largest specialty organization exclusively representing dermatologic surgeons who have unique training and experience to treat the health, function and beauty of your skin. ASDS members are pioneers in the field. Many are involved in the clinical studies that bring popular treatments to revitalize skin and fill and diminish wrinkles to the forefront. Their work has helped create and enhance many of the devices that remove blemishes, hair and fat, and tighten skin. Dermatologic surgeons also are experts in skin cancer prevention, detection and treatment. As the incidence of skin cancer rises, dermatologic surgeons are committed to taking steps to minimize the life-threatening effects of this disease. For more information, visit asds.net
The Benefits of SRT
Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:
- 95%+ cure rates that rival surgery
- No anesthesia, cutting, bleeding, stitching or pain
- No downtime or lifestyle restrictions
- Super cosmesis, no unsightly scarring
- No need for post-treatment reconstructive surgeries